Vanderbilt-Incyte Research Alliance Program Grant – LOI DUE 1/29/18
January 19, 2018
The Vanderbilt–Incyte Research Alliance announces a funding opportunity to support faculty in the areas of applied and translational research. The Vanderbilt–Incyte Research Alliance is built on a shared mission that science drives success. Incyte’s world-class drug discovery expertise, investment in sound and precise science, and rigorous pursuit of excellence in research and development drive efforts to identify new molecules with the potential to improve the lives of patients and make a difference in health care. These efforts have led to the discovery and clinical development of a broad range of targeted and immuno-therapies, more details of which can be found at: https://www.incyte.com/what-we-do/discover.aspx.
Qualified faculty are encouraged to apply for research funds made available through the Vanderbilt-Incyte Research Alliance Program Grant. The goal of these funds is to support faculty in the areas of applied and translational research specifically in the following areas:
- Identification and validation of novel, tumor-cell intrinsic therapeutic intervention points
- Characterization of the role(s) for epigenetic modification in cell growth, proliferation, drug resistance and/or survival
- Characterization of the role(s) for tumor cell-intrinsic, inflammatory signaling in cancer growth, proliferation, drug resistance and/or survival
- Novel molecular methods (e.g. imaging, gene expression, etc.) to improve patient selection and stratification for clinical trials
Multiple grants will be awarded for projects beginning March 1, 2018 and ending December 31, 2018. Funding allocations for 2018 will be approximately $100,000 (direct costs) per project.
For the first step in the process, we are requesting interested applicants electronically submit a single PDF containing all LOI documentation through the VICC Pilot Project Application Portal by midnight January 29, 2018. Instructions and application forms can be found attached to this email.
If you have any questions or require clarification, please contact M. Allison Bowen (email@example.com).